Ascendis Pharma (NASDAQ: ASND) holder files to sell 86,860 ADS

Rhea-AI Filing Summary

Ascendis Pharma A/S shareholder Jan Mikkelsen has filed a Form 144 notice to sell 86,860 American Depositary Shares on Nasdaq through Citigroup Global Markets. These ADS were acquired on 01/13/2026 through a restricted stock and performance stock unit compensation program, with the same date listed for acquisition and payment, and compensation noted as the nature of payment.

The notice also reports that during the past three months, Mikkelsen sold 100,000 American Depositary Shares on 12/02/2025, generating gross proceeds of 20675000.00. The filing states that the person on whose behalf the securities are to be sold represents that they do not know any material adverse information about Ascendis Pharma A/S that has not been publicly disclosed.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
AMERICAN DEPOSITORY SHARES	CITIGROUP GLOBAL MARKETS 390 GREENWICH ST NEW YORK NY 10013	86860	18413630.85	61695211	01/13/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
AMERICAN DEPOSITORY SHARES	01/13/2026	RESTRICTED STOCK AND PERFORMANCE STOCK UNIT PROGRAM	ASCENDIS PHARMA A/S			86860	01/13/2026	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
MIKKELSEN JAN MOLLER TUBORG BOULEVARD 12 HELLERUP G7 DK2900	AMERICAN DEPOSITORY SHARES	12/02/2025	100000	20675000.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for ASND disclose?

The Form 144 filing discloses that Jan Mikkelsen intends to sell 86,860 American Depositary Shares of Ascendis Pharma A/S (ASND) on NASDAQ through Citigroup Global Markets.

How many Ascendis Pharma (ASND) shares are planned to be sold under this Form 144?

The filing reports a planned sale of 86,860 American Depositary Shares of Ascendis Pharma A/S.

How and when were the ASND shares in this Form 144 acquired?

The 86,860 ADS were acquired on 01/13/2026 through a restricted stock and performance stock unit program from Ascendis Pharma A/S, with the nature of payment listed as compensation.

What prior sales by the same seller are disclosed in the ASND Form 144?

The document reports that Jan Mikkelsen sold 100,000 American Depositary Shares on 12/02/2025, generating gross proceeds of 20675000.00.

What representation does the seller make about Ascendis Pharma in this Form 144?

The person for whose account the securities are to be sold represents that they do not know any material adverse information about the current or prospective operations of Ascendis Pharma A/S that has not been publicly disclosed.

On which exchange will the ASND shares in this Form 144 be sold and who is the broker?

The American Depositary Shares are listed to be sold on NASDAQ with Citigroup Global Markets named as the broker.